{
  "first_published_at": "2009-11-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087898", 
  "title": "Orciprenaline sulphate (Alupent): withdrawal due to unfavourable benefit-risk profile", 
  "tags": "{\"parsed_therapeutic\": [\"respiratory-disease-allergy\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Respiratory disease and allergy\"]}", 
  "_document_number": 233, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/withdrawal_icon.png", 
  "therapeutic_area": [
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Orciprenaline sulphate (Alupent): withdrawal due to unfavourable benefit-risk profile</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Orciprenaline sulphate is to be withdrawn over the next year because a review has concluded that the benefit-risk profile is unfavourable. Patients who require a liquid oral formulation of a &#946;-agonist should be switched to a more-selective short-acting &#946;<sub>2</sub>-agonist such as salbutamol or terbutaline<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Orciprenaline sulphate is to be withdrawn over the next year because a review has concluded that the benefit-risk profile is unfavourable. Patients who require a liquid oral formulation of a &#946;-agonist should be switched to a more-selective short-acting &#946;<font class=\"sub\">2</font>-agonist such as salbutamol or terbutaline</p><p>Orciprenaline sulphate (Alupent) is a non-specific &#946;-agonist indicated for reversible airways obstruction and suggested for maintenance therapy. It is currently available for oral administration as a syrup.</p><p>An analysis of the available literature demonstrated that orciprenaline sulphate is significantly less efficacious than salbutamol in terms of both the extent and duration of bronchodilation. Yellow Card reports and clinical trial data show a significantly increased incidence of cardiac side effects, mainly palpitations and tachycardia because of its non-selectivity. Importantly, clinical trial data show that cardiac side effects occur before maximum bronchodilation is achieved because of its non-selectivity.</p><p>Accordingly, the Commission on Human Medicines (CHM) has advised that the balance of benefit and risks for orciprenaline sulphate is no longer favourable and concluded that:</p><ul>\r\n\t\t\t<li>there should be a planned withdrawal of orciprenaline sulphate from the UK market</li>\r\n\t\t\t<li>there are no patient groups for whom transfer to a more-selective &#946;<font class=\"sub\">2</font>-agonist would be inappropriate</li></ul><p>The MHRA is working with the manufacturer to achieve a planned voluntary withdrawal of orciprenaline sulphate over the next year. The product will continue to be available for several months, but it is recommended that patients are switched to a more-selective &#946;<font class=\"sub\">2</font>-agonist at the earliest opportunity.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Orciprenaline sulphate is to be withdrawn from the UK market over the next year</li>\r\n\t\t\t\t<li>Patients who require a liquid oral formulation of a &#946;-agonist should be switched to a more-selective short-acting &#946;<font class=\"sub\">2</font>-agonist such as salbutamol or terbutaline</li>\r\n\t\t\t</ul></div><p>See <em>Wolfe JD, et al. Pediatrics 1991; 88: 312&ndash;19.</em></p><p><a href=\"/Opendocuments/OpenPDFdocuments/CON062531\">Further information is also&nbsp;available in an assessment report on this topic</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Nov 2009, vol 3 issue 4: 6.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Orciprenaline sulphate is to be withdrawn over the next year because a review has concluded that the benefit-risk profile is unfavourable. Patients who require a liquid oral formulation of a &#946;-agonist should be switched to a more-selective short-acting &#946;<font class=\"sub\">2</font>-agonist such as salbutamol or terbutaline</p><p>Orciprenaline sulphate (Alupent) is a non-specific &#946;-agonist indicated for reversible airways obstruction and suggested for maintenance therapy. It is currently available for oral administration as a syrup.</p><p>An analysis of the available literature demonstrated that orciprenaline sulphate is significantly less efficacious than salbutamol in terms of both the extent and duration of bronchodilation. Yellow Card reports and clinical trial data show a significantly increased incidence of cardiac side effects, mainly palpitations and tachycardia because of its non-selectivity. Importantly, clinical trial data show that cardiac side effects occur before maximum bronchodilation is achieved because of its non-selectivity.</p><p>Accordingly, the Commission on Human Medicines (CHM) has advised that the balance of benefit and risks for orciprenaline sulphate is no longer favourable and concluded that:</p><ul>\r\n\t\t\t<li>there should be a planned withdrawal of orciprenaline sulphate from the UK market</li>\r\n\t\t\t<li>there are no patient groups for whom transfer to a more-selective &#946;<font class=\"sub\">2</font>-agonist would be inappropriate</li></ul><p>The MHRA is working with the manufacturer to achieve a planned voluntary withdrawal of orciprenaline sulphate over the next year. The product will continue to be available for several months, but it is recommended that patients are switched to a more-selective &#946;<font class=\"sub\">2</font>-agonist at the earliest opportunity.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Orciprenaline sulphate is to be withdrawn from the UK market over the next year</li>\r\n\t\t\t\t<li>Patients who require a liquid oral formulation of a &#946;-agonist should be switched to a more-selective short-acting &#946;<font class=\"sub\">2</font>-agonist such as salbutamol or terbutaline</li>\r\n\t\t\t</ul></div><p>See <em>Wolfe JD, et al. Pediatrics 1991; 88: 312&#8211;19.</em></p><p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con062531.pdf\" target='new\"\"'>Further information is also&#160;available in an assessment report on this topic<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (269Kb)</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Nov 2009, vol 3 issue 4: 6.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-11-01", 
  "date_last_modified": "2010-08-27", 
  "_assets": [], 
  "_item_id": 233, 
  "summary": "Orciprenaline sulphate is to be withdrawn over the next year because a review has concluded that the benefit-risk profile is unfavourable. Patients who require a liquid oral formulation of a β-agonist should be switched to a more-selective short-acting β2-agonist such as salbutamol or terbutaline", 
  "body": "Article date: November 2009\n\nOrciprenaline sulphate is to be withdrawn over the next year because a review has concluded that the benefit-risk profile is unfavourable. Patients who require a liquid oral formulation of a β-agonist should be switched to a more-selective short-acting β2-agonist such as salbutamol or terbutaline\n\nOrciprenaline sulphate (Alupent) is a non-specific β-agonist indicated for reversible airways obstruction and suggested for maintenance therapy. It is currently available for oral administration as a syrup.\n\nAn analysis of the available literature demonstrated that orciprenaline sulphate is significantly less efficacious than salbutamol in terms of both the extent and duration of bronchodilation. Yellow Card reports and clinical trial data show a significantly increased incidence of cardiac side effects, mainly palpitations and tachycardia because of its non-selectivity. Importantly, clinical trial data show that cardiac side effects occur before maximum bronchodilation is achieved because of its non-selectivity.\n\nAccordingly, the Commission on Human Medicines (CHM) has advised that the balance of benefit and risks for orciprenaline sulphate is no longer favourable and concluded that:  \n  \n  * there should be a planned withdrawal of orciprenaline sulphate from the UK market  \n  * there are no patient groups for whom transfer to a more-selective β2-agonist would be inappropriate  \n  \nThe MHRA is working with the manufacturer to achieve a planned voluntary withdrawal of orciprenaline sulphate over the next year. The product will continue to be available for several months, but it is recommended that patients are switched to a more-selective β2-agonist at the earliest opportunity.\n\nAdvice for healthcare professionals:  \n  \n  * Orciprenaline sulphate is to be withdrawn from the UK market over the next year  \n  * Patients who require a liquid oral formulation of a β-agonist should be switched to a more-selective short-acting β2-agonist such as salbutamol or terbutaline  \n  \nSee Wolfe JD, et al. Pediatrics 1991; 88: 312–19.\n\n[Further information is also available in an assessment report on this topic](http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con062531.pdf) (269Kb)\n\n \n\nArticle citation: Drug Safety Update Nov 2009, vol 3 issue 4: 6.\n"
}